Adipose-derived mesenchymal stem cells treatments for fibroblasts of fibrotic scar via downregulating TGF-β1 and Notch-1 expression enhanced by photobiomodulation therapy

What the authors concluded

In summary, the study demonstrates that in vitro LLLT applied to Adipose Mesenchymal Stem Cells (AMSCs) boosts its secretion of paracrine factors, thereby enhancing AMSCs potential as a treatment for keloid fibroblasts and hypertrophic scar fibroblasts via downregulation of Notch1 and TGF-β1. However, there are limitations of this study that needs further amelioration. Following research is find

Devices that emit this wavelength

Matched on wavelength within 15nm, since LED bins vary by roughly that much and a tighter match would be false precision. Where we have an irradiance figure, the session length is the time needed to reach this study's dose of 4 J/cm² at that intensity.

Matching a wavelength is not the same as reproducing a trial. Session times assume the device's published irradiance is accurate at the distance it was measured, which on brand-claim figures is often optimistic. Where a device publishes both a peak and an average we use the average, and where it publishes a falloff curve we use the lowest figure, so these times run long rather than short. Clinical protocols also control for spot size, contact and skin type in ways a home device cannot.